Tensions Between Nonobviousness and Written Description in U.S. Patent Law
October 27, 2020
| Duane Morris LLP
Duane Morris is hosting the webinar, "Tensions Between Nonobviousness and Written Description in U.S. Patent Law," on Tuesday, October 27, 2020, from 12:00 p.m. to 1:00 p.m. Eastern.
About the Program
United States patent law establishes requirements that inventors and applicants must satisfy to obtain a patent, which include utility, recitation of patent eligible subject matter, novelty, nonobviousness, an adequate written description, enablement and the best mode of practicing the invention. Biogen International GmbH v. Mylan Pharmaceuticals, Inc. presents an example of tensions between the nonobviousness and written description requirements.
This webinar will discuss the background on this case, including claims at issue and Biogen’s prosecution strategy, and the best practices and lessons learned from the court decision.
We invite you to read the Duane Morris Alert, “Playing Your Cards Right: Arguments Against Obviousness Can Be Detrimental for Satisfying the Written Description Requirement,” which was republished in the Intellectual Property & Technology Law Journal.
Deborah L. Lu, Ph.D., Partner, Duane Morris LLP
Thomas J. Kowalski, Partner, Duane Morris LLP
Heidi Lunasin, Special Counsel, Duane Morris LLP
Brandon A. Chan, Ph.D., Associate, Duane Morris LLP
About Duane Morris
Duane Morris LLP, a law firm with more than 800 attorneys in offices across the United States and internationally, is asked by a broad array of clients to provide innovative solutions to today’s legal and business challenges. Our lawyers represent clients in patent disputes in the life sciences industry and involving a wide variety of complex technologies, including biotechnology processes and products, pharmaceuticals, medical devices, business systems and methods, to name a few.